Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway - A report of the tumour angiogenesis research group

Journal of Clinical Oncology

Volumn 24, Issue 26, 2006, Pages 4301-4308

  Koukourakis, Michael I ^a   Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a   Gatter, Kevin C ^a   Harris, Adrian L ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; HIF1A PROTEIN, HUMAN; ISOENZYME; PROTEIN KINASE INHIBITOR; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; ADENOCARCINOMA; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COLORECTAL TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; STATISTICAL MODEL; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; ISOENZYMES; L-LACTATE DEHYDROGENASE; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33749027749     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.9501     Document Type: Article

References (59)

1. Garfinkel L, Mushinski M: US cancer incidence, mortality and survival: 1973-1996. Stat Bull Metrop Insur Co 80:23-32, 1999
2. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004
3. Minsky BD: Adjuvant therapy of resectable rectal cancer. Cancer Treat Rev 28:181-188, 2002
4. Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004
5. Willett C, Tepper JE, Cohen A, et al: Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys 10:645-651, 1984
6. Pilipshen SJ, Heilweil M, Quan SH, et al: Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 53:1354-1362, 1984
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
8. Molina R, Barak V, van Dalen A, et al: Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 26: 281-293, 2005
9. Mass RD, Press MF, Anderson S, et al: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240-246, 2005
10. Hecht JR, Trarbach T, Jaeger E, et al: A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23:XXX, 2005 (suppl: abstr LBA3)
11. Zaman K, Ryu H, Hall D, et al: Protection from oxidative stress-induced apoptosis in cortical neuronal culturesby iron chelators is associated with enhanced DNA binding of hypoxia-induciblefactor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19:9821-9830, 1999
12. Talks KL, Turley H, Gatter KC, et al: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421, 2000
13. Turley H, Scott PA, Watts VM, et al: Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186:313-318, 1998
14. Stewart M, Turley H, Cook N, et al: The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation: An immunohistochemical study. Histopathology 43:33-39, 2003
15. Parums DV, Cordell JL, Micklem K, et al: JC70: A new monoclonal antibody that detects vascular endothelium associatednantigen on routinely processed tissue sections. J Clin Pathol 43: 752-757, 1990
16. Koukourakis MI, Giatromanolaki A, Simopoulos C, et al: Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22:25-30, 2005
17. Sivridis E, Giatromanolaki A, Koukourakis MI: Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J Clin Pathol 58:1033-1038, 2005
18. Giatromanolaki A, Sivridis E, Minopoulos G, et al: Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clin Cancer Res 8:1185-1191, 2002
19. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al: C-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 10:7972-7977, 2004
20. Holbrook JJ, Liljas A, Steindel SJ, et al: Lactate dehydrogenase, in Boyer PD (ed), The Enzymes, Vol XI (ed 3). Academic Press, NY, 1975, pp. 191-292
21. Koukourakis MI, Giatromanolaki A, Sivridis E: Tumour and Angiogenesis Research Group: Lactate dehydrogenase isoenzymes 1 and 5-Differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 24:199-202, 2003
22. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Tumor and Angiogenesis Research Group: Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 7:1-6, 2005
23. Koukourakis MI, Giatromanolaki A, Harris AL, et al: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role of tumor-associated stroma. Cancer Res 66:632-637, 2006
24. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Tumour and Angiogenesis Research Group: Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89:877-885, 2003
25. Suarez-Kurtz G: Enzyme release from skeletal muscle. Braz J Med Biol Res 16:283-290, 1983
26. Takami H, Matsuda H, Kuki S, et al: Leakage of cytoplasmic enzymes from rat heart by the stress of cardiac beating after increase in cell membrane fragility by anoxia. Pflugers Arch 416:144-150, 1990
27. Bacci G, Longhi A, Ferrari S, et al: Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: Experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori 90:478-484, 2004
28. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
29. Tas F, Aykan F, Alici S, et al: Prognostic factors in pancreatic carcinoma: Serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24:547-550, 2001
30. van Dijk MR, Steyerberg EW, Stenning SP, et al: Survival of patients with nonseminomatous germ cell cancer: A review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer 90:1176-1183, 2004
31. Yuce K, Baykal C, Genc C, et al: Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol 22:228-232, 2001
32. Brizel DM, Schroeder T, Scher RL, et al: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:349-353, 2001
33. Cheng SH, Jian JJ, Tsai SY, et al: Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 41:755-762, 1998
34. Kushner BH, LaQuaglia MP, Modak S, et al: Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Med Pediatr Oncol 41:80-82, 2003
35. Lutterbach J, Sauerbrei W, Guttenberger R: Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 179:8-15, 2003
36. Bacci G, Ferrari S, Bertoni F, et al: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4-11, 2000
37. Hauschild A, Michaelsen J, Brenner W, et al: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155-161, 1999
38. Kondo E, Ogura M, Kagami Y, et al: Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol 73:363-368, 2001
39. Wilder RB, Rodriguez MA, Ha CS, et al: Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91:2440-2446, 2001
40. Ryberg M, Nielsen D, Osterlind K, et al: Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12:81-87, 2001
41. Gupta D, Lammersfeld CA, Vashi PG, et al: Prognostic significance of subjective global assessment (SGA) in advanced colorectal cancer. Eur J Clin Nutr 59:35-40, 2005
42. Lin JT, Wang WS, Yen CC, et al: Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol 20:900-905, 2005
43. Diaz R, Aparicio J, Girones R, Molina J, et al: Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 5:197-202, 2005
44. Semenza G: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993-998, 2002
45. Semenza GL, Jiang BH, Leung SW, et al: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529-32537, 1996
46. Forsythe JA, Jiang BH, Iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613, 1996
47. Martinez-Zaguilan R, Seftor EA, et al: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14:176-186, 1996
48. Rozhin J, Sameni M, Ziegler G, et al: Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54:6517-6525, 1994
49. Lu H, Dalgard CL, Mohyeldin A, et al: Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280:41928-41939, 2005
50. Elstrom RL, Bauer DE, Buzzai M, et al: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892-3899, 2004
51. Pore N, Liu S, Shu HK, et al: Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15:4841-4853, 2004
52. Mizukami Y, Li J, Zhang X, et al: Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64:1765-1772, 2004
53. Brekken RA, Huang X, King SW, et al: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58:1952-1959, 1998
54. Fox SB, Turley H, Cheale M, et al: Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202:313-320, 2004
55. Weigand M, Hantel P, Kreienberg R, et al: Autocrine vascular endothelial growth factor signaling in breast cancer: Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8:197-204, 2005
56. Siatskas C, Underwood J, Ramezani A, et al: Specific pharmacological dimerization of KDR in lentivirally transduced humanhematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J 19:1752-1754, 2005
57. Zhang H, Li Y, Li H, Bassi R, et al: Inhibition of both the autocrine and the paracrine growth of human leukaemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma 45:1887-1897, 2004
58. Giatromanolaki A, Sivridis E, Brekken R, et al: Tumour and Angiogenesis Research Group: The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: Prognostic and therapeutic implications. Cancer 92:2569-2577, 2001
59. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088-3095, 2000